The US Food and Drug Administration (FDA) has approved NeuroBo Pharmaceuticals’ investigational new drug (IND) application for DA-1726 to commence a Phase I clinical trial to treat obesity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,